WO2001018200A1 - Gene de type tsg - Google Patents
Gene de type tsg Download PDFInfo
- Publication number
- WO2001018200A1 WO2001018200A1 PCT/JP2000/006050 JP0006050W WO0118200A1 WO 2001018200 A1 WO2001018200 A1 WO 2001018200A1 JP 0006050 W JP0006050 W JP 0006050W WO 0118200 A1 WO0118200 A1 WO 0118200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- present
- dna
- seq
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel TSG-like protein derived from the mouse embryo AGM region and its gene.
- Hematopoiesis in the early fetal period of mice occurs in the yolk sac and fetal liver. Hematopoiesis in the yolk sac mainly produces nucleated fetal red blood cells and is called fetal hematopoiesis. Hematopoiesis in fetal liver, on the other hand, produces all cell lines except nucleated fetal red blood cells, and is called adult hematopoiesis.
- LTR-HSC long-term repopulating hematopoietic stem cell
- the present invention provides a novel TSG-like protein derived from the mouse embryo AGM region and a gene thereof.
- the present invention also provides a vector into which the gene is inserted, a host cell carrying the vector, and an antibody that binds to the protein. Further, the present invention provides A method for screening a compound such as a receptor that binds to the protein using the protein is provided.
- the present inventors have developed a signal sequence trap (SST) method (Japanese Patent Application No. 9-324912) developed in-house to search for a gene having a new signal sequence from the mouse embryo AGM region. Utilizes mouse embryo AGM-derived poly A
- TSG gene is one of the dorsal determinants of the embryo, and is known to determine the differentiation of dorsal midline cel cel by interacting with DPP (the county part of BMP2 / 4).
- DPP the county part of BMP2 / 4
- TSG protein binds to BMP (Oelgeschlager M. et al.
- the isolated TSG-like gene is structurally similar to the TSG gene. Sex is expected to interact with BM P2 / 4.
- the isolation of this TSG-like gene from the mouse embryo AGM region suggests that it is involved in the development of hematopoietic stem cells. Therefore, the TSG-like protein of the present invention is useful as a tool for purification and screening of factors involved in the development of hematopoietic stem cells, and also for screening drug candidate compounds for immune and hematopoietic system-related diseases.
- the present invention relates to novel TSG-like proteins and their genes, and their production and use.
- (c) has an amino acid sequence in which one or more amino acids have been substituted, deleted, inserted, and / or added in the amino acid sequence of SEQ ID NO: 2, and SEQ ID NO: 2 DNA encoding a protein functionally equivalent to the protein consisting of the amino acid sequence described in 1.
- nucleotide having a chain length of at least 15 bases which hybridizes with a DNA consisting of the base sequence of SEQ ID NO: 1 or a complementary strand thereof
- the present invention relates to a novel protein having homology to Drosophila TSG gene.
- the nucleotide sequence of the mouse-derived cDNA isolated by the present inventors is shown in SEQ ID NO: 1, and the amino acid sequence of the protein encoded by the cDNA is shown in SEQ ID NO: 2.
- This protein has a signal sequence at its N-terminus and is homologous to the TSG protein, the dorsal determinant of Drosophila embryos.
- a signal of about 4.0 kb was observed in heart, lung, liver, and kidney.
- This protein was isolated from the AGM region of the embryo, was expressed in the early embryo, had homology to the TSG protein, and was presumed to interact with BMP2 / 4. This protein is necessary for system differentiation, and also because the TSG protein binds to BMP and promotes BMP signaling activity (Oelgeschlager M. et al. (2000) Nature 405, 757-763). Is suggested to be involved in hematopoietic cell differentiation and bone formation.
- this protein is used for the purification and cloning of proteins related to the development of hematopoietic stem cells, bone formation, etc., and also for the screening of candidate compounds for therapeutic drugs such as immune and hematopoietic diseases and bone formation-related diseases. Can be used as a useful tool.
- the present invention also includes a protein functionally equivalent to the protein of SEQ ID NO: 2.
- proteins include, for example, homologous proteins of other organisms corresponding to the protein of SEQ ID NO: 2 and variants of the protein of SEQ ID NO: 2.
- “functionally equivalent” refers to the activity of rescuing the differentiation of dorsal midline cells when the target protein is injected into a Drosophila TSG mutant, (Xenopus) Refers to the ability to control embryo development (eg, dorsoventral induction) when injected into eggs.
- the protein of the present invention binds to BMP (bone morphogenetic protein; DPP) and binds to BMP signaling activity. (Oelgeschlager M. et al. (2000) Nature 405, 757-763) is also suggested.
- a protein having an amino acid sequence in which one or more amino acids are mutated in the amino acid sequence of SEQ ID NO: 2 and functionally equivalent to the protein of SEQ ID NO: ⁇ : 2 is also described in the present invention. Included in the proteins of the invention.
- the number of amino acids to be mutated in such a mutant is generally within 30 amino acids, preferably within 15 amino acids, more preferably within 5 amino acids, and even more preferably within 3 amino acids. Conceivable. Further, it is desirable that the amino acid residue to be mutated is mutated to another amino acid in which the properties of the amino acid side chain are conserved.
- the properties of the amino acid side chain include hydrophobic amino acids (A, I, L, M, F, P, W, Y, V) and hydrophilic amino acids (R, D, N, C, E, Q, G , H, K, S, T), an amino acid having an aliphatic side chain (G, A, V, L, I, P), an amino acid having a hydroxyl group-containing side chain (S, ⁇ , ⁇ ), a sulfur atom-containing side Amino acids with chain ( ⁇ ), carboxylic acids and amino acids with amide-containing side chains (D, N, E, Q), amino acids with base-containing side chains (R, K, ⁇ ), aromatic ⁇ ⁇ ⁇ ⁇ Amino acids with side chains
- Examples of the protein having one or more amino acid residues added to the protein of SEQ ID NO: 2 include a fusion protein containing the protein of SEQ ID NO: 2.
- the fusion protein is a fusion of the protein of SEQ ID NO: 2 with another peptide or protein and is included in the present invention.
- the method for producing a fusion protein is as follows: MA encoding the protein of the present invention and DNA encoding another peptide or protein are ligated in frame so that they are introduced into an expression vector and expressed in a host. Any known method can be used. Other peptides or proteins to be fused with the protein of the present invention are not particularly limited.
- peptides to be fused with the protein of the present invention include, for example, FLAG
- 6 x His consisting of 6 His (histidine) residues, 10 x His, influenza agglutinin (HA), human c -myc fragment, VSV-GP fragment, pl8HIV fragment, T7-tag, HSV-tag, E-tag ⁇ SV40T antigen fragment, lck tag, hy-tubulin fragment, B-tag, Protein C fragment And other known peptides can be used.
- proteins to be fused with the protein of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza agglutinin), immunoglobulin constant region, 5-galactin And the like, for example, peptidase and MBP (maltose binding protein).
- a fusion protein can be prepared by fusing a commercially available DNA encoding the peptide or protein with a DNA encoding the protein of the present invention, and expressing the fusion DNA prepared thereby.
- a protein that encodes a DNA sequence encoding the protein of SEQ ID NO: 2 or a DNA that hybridizes with a DNA consisting of a part thereof, which is functionally identical to the protein of SEQ ID NO: 2 are also included in the protein of the present invention.
- proteins include, for example, homologs of mammals other than mouse (eg, proteins encoded by human genes).
- Hybridization for isolating DNA encoding a functionally equivalent protein can be performed, for example, under the conditions that the stringency is 10% formamide, 5xSSPE, lx Denhardt's solution, and lx salmon sperm DNA. More preferred conditions (more stringent conditions) include 25% formamide, 5xSSPE, lx Denhardt's solution, and lx salmon sperm DNA. More preferred conditions (more stringent conditions) are 50% % The conditions are formamide, 5xSSPE, lx Denhardt's solution, and lx salmon sperm DNA.
- the protein functionally equivalent to the protein of SEQ ID NO: 2, which is isolated by the hybridization technique or the gene amplification technique and whose DNA encodes SEQ ID NO: 2, is usually a protein and an amino acid of SEQ ID NO: 2. It has high homology in sequence.
- the protein of the present invention also includes a protein that is functionally equivalent to the protein of SEQ ID NO: 2 and that has high homology to the amino acid sequence of SEQ ID NO: 2.
- High homology refers to amino acid sequence identity of 40% or more, preferably 50% or more, and more preferably 60% or more.
- the protein of the present invention may differ in amino acid sequence, molecular weight, isoelectric point, presence / absence and form of sugar chains, etc., depending on the cell, host, or purification method that produces the protein as described below. However, as long as the obtained protein has a function equivalent to that of the protein of SEQ ID NO: 2, it is included in the present invention.
- a prokaryotic cell for example, Escherichia coli
- a methionine residue is added to the N-terminal of the amino acid sequence of the original protein.
- the N-terminal signal sequence is removed.
- the protein of the present invention includes such a protein.
- the signal sequence was estimated to be from Met at position 1 to Ser at position 24 in the amino acid sequence of SEQ ID NO: 2. Accordingly, the present invention includes a protein consisting of Cys at position 25 to Phe at position 222 in the amino acid sequence of SEQ ID NO: 2.
- the protein of the present invention can be prepared as a recombinant protein or as a natural protein by methods known to those skilled in the art. If it is a recombinant protein, the protein of the present invention is secreted extracellularly, for example, as a soluble protein. Next, the culture supernatant of the cells was collected, concentrated, and then subjected to ion exchange, reverse phase, Purification can be achieved by chromatography such as gel filtration, or by affinity chromatography in which an antibody against the protein of the present invention is immobilized on a column, or by combining a plurality of these columns. is there.
- the protein of the present invention is expressed and expressed in a host cell (for example, animal cell or Escherichia coli) as a fusion protein with glutathione S-transferase protein or as a recombinant protein to which a plurality of histidines are added. Purify the recombinant protein using a glutathione column or a nickel column. Thereafter, if necessary, a region other than the target protein in the fusion protein can be prepared by a method of cleaving with thrombin or Factor-1 Xa and removing it. If it is a natural protein, it can be isolated by, for example, allowing an extract of a cell expressing the protein of the present invention to act on an affinity column to which the antibody of the present invention described below is bound and purifying the protein. .
- the present invention also includes partial peptides of the protein of the present invention.
- the partial peptide of the present invention comprises an amino acid sequence of at least 7 amino acids, preferably 8 amino acids or more, more preferably 9 amino acids or more.
- the partial peptide may be prepared, for example, by preparing an antibody against the protein of the present invention, screening a compound that binds to the protein of the present invention, screening for the receptor for the protein of the present invention, or competing for the protein of the present invention. It can be used for preparation of inhibitors. Also included, for example, are partial peptides that have the ability to bind to the receptor but have no ability to activate the receptor (function as a competitive inhibitor of the protein of the present invention).
- the partial peptide of the present invention can be produced by a gene engineering technique, a known peptide synthesis method, or by cleaving the protein of the present invention with an appropriate peptide.
- the present invention also relates to an MA encoding the protein of the present invention.
- the DNA of the present invention is used for in vivo and in vitro production of the protein of the present invention as described above, and also includes, for example, gene therapy for diseases caused by abnormality of the gene encoding the protein of the present invention. It can also be applied to The DNA of the present invention is Any form can be used as long as it can encode protein. That is, it does not matter whether it is cDNA synthesized from mA, genomic DNA, or chemically synthesized DNA. Further, as long as it can encode the protein of the present invention, a DNA having an arbitrary base sequence based on the degeneracy of the genetic code is included.
- the MA of the present invention can be prepared by a method known to those skilled in the art.
- a cDNA library is prepared from cells expressing the protein of the present invention, and a part of the DNA sequence of the present invention (for example, the DNA sequence of SEQ ID NO: 1) is used as a probe to generate a hybridase. It can be prepared by performing chilling.
- the cDNA library may be prepared, for example, by the method described in Sambrook, J. et al., Molecular Clomng, Cold Spring Harbor Laboratory Press (1989), or a commercially available DNA library may be used.
- RNA is prepared from cells expressing the protein of the present invention, and oligo DNA is synthesized based on the sequence of the DNA of the present invention (for example, the DNA sequence of SEQ ID NO: 1). It can also be prepared by performing a PCR reaction and amplifying the cDNA encoding the protein of the present invention.
- Genomic DNA can be isolated by screening a genomic DNA library using the obtained cDNA as a probe.
- mRNA is isolated from cells, organs and the like that express the protein of the present invention (eg, organs such as heart, lung, liver, kidney, etc., embryos).
- mRNA can be isolated by known methods, for example, guanidine ultracentrifugation (Chirg win, JM et al., Biochemistry (1979) 18, 5294-5299), AGPC method (Chomczynski, P. and Sacchi, N., Anal.Biochem. (1987) 162, 156-159), prepare total RNA, and use mRNA Purification Kit (Pharmacia) etc. to obtain total mRNA. Purify NA.
- mRNA can be directly prepared using the QuickPrep mRNA Purification Kit (Pharmacia).
- CDNA is synthesized from the obtained mRNA using reverse transcriptase.
- cDNA can also be synthesized using AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Corporation) or the like.
- the 5'-Ampli FINDER RACE Kit (Clontech) and the polymerase chain reaction (PCR) using the synthetic DNA as a primer 5 and the -RACE method (Frohman, MA et al.) Acad. Sci. USA (1988) 85, 8998-9002; cDNA synthesis and synthesis according to Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932). Amplification can be performed.
- a target DNA fragment is prepared from the obtained PCR product, and ligated to the vector DNA. Further, a recombinant vector is prepared from this, introduced into E. coli, etc., and colonies are selected to prepare a desired recombinant vector.
- the base sequence of the target DNA can be confirmed by a known method, for example, the dideoxynucleotide chain termination method.
- a nucleotide sequence having higher expression efficiency can be designed in consideration of the codon usage of the host used for expression (Grantham, R. et al., Nuclear Acids Research ( 1981) 9, r43-74).
- the DNA of the present invention can be modified by a commercially available kit or a known method. Modifications include, for example, digestion with restriction enzymes, insertion of synthetic oligonucleotides or appropriate DNA fragments, addition of a linker, insertion of an initiation codon (ATG) and / or termination codon (TM, TGA, or TAG). And the like.
- the DNA of the present invention includes a DNA consisting of base A at position 87 to base T at position 752 in the base sequence of SEQ ID NO: 1, and a DNA consisting of base T at position 752 to base T at position 159.
- the DNA of the present invention is a DNA that hybridizes under stringent conditions with a DNA consisting of the nucleotide sequence of SEQ ID NO: 1 and a protein functionally equivalent to the protein of SEQ ID NO: 2. Includes MA.
- the conditions for hybridization include the above conditions.
- the hybridizing DNA may preferably be a naturally occurring DNA, such as a cDNA or a chromosomal DNA.
- the DNA of the present invention can be used for producing the protein of the present invention as a recombinant protein. If the DNA encoding the protein of the present invention is defective, application to antisense function inhibition, gene therapy for replacement with a normal gene, and the like can be considered.
- the present invention also relates to a vector into which the DNA of the present invention has been inserted.
- a vector of the present invention it is useful for retaining the DNA of the present invention in host cells or expressing the protein of the present invention.
- Escherichia coli when Escherichia coli is used as a host, the vector is amplified in large amounts in Escherichia coli (e.g., JM109, DH5, HB10K XLlBlue), etc.
- Escherichia coli e.g., JM109, DH5, HB10K XLlBlue
- the restriction is not particularly limited as long as the gene has an “ori” of the above and has a transformed gene selected from Escherichia coli (eg, a drug-resistant gene that can be identified by any drug (ampicillin, tetracycline, kanamycin, chloramphenicol)). Absent.
- vectors include M13-based vectors, pUC-based vectors, pB322, pBluescript, pCR-Script, and the like.
- pGEM-T When subcloning or excision of cDNA is intended, in addition to the above vectors, for example, pGEM-T, pDIRECT, pT7 and the like can be mentioned.
- an expression vector is particularly useful.
- the host in addition to having the above characteristics such that the vector is amplified in Escherichia coli, the host may be JM109, DH5, HB101, XLl-Blue.
- a promoter that can be efficiently expressed in Escherichia coli such as the lacZ promoter (Ward et al., Nature (1989) 341, 544-546; it is essential to have FASEB J. (1992) 6, 2422-2427), araB promoter (Better et al., Science (1988) 240, 1041-1043), or T7 promoter.
- Such vectors include, in addition to the above vectors, pGEX-5X-1 (Pharmacia), Factory QIAexpress systemj (Qiagen), pEGFP, or pET (in this case, the host is BL21 expressing T7 RNA polymerase. Is preferred) and the like.
- the vector may also include a signal sequence for polypeptide secretion.
- a signal sequence for protein secretion a pelB signal sequence (Lei, SP et al J. Bacterid. (1987) 169, 4379) may be used for production in E. coli periplasm.
- the introduction of the vector into the host cell can be performed using, for example, the calcium chloride method or the electroporation method.
- a vector for producing the protein of the present invention a mammalian expression vector (for example, pcDNA3 (Invitrogen)) or pEGF-BOS (Nucleic Acids. Res.
- insect cell-derived expression vector eg, "Bac-to-BAC baculovirus expression systemj (GI BCO BRL), pBacPAK8), plant-derived expression Vector (eg, ⁇ 1, pMH2), animal virus-derived expression vector (eg, pHSV, pMV, pAdexLcw), retrovirus-derived expression vector (eg, pZIpneo), yeast-derived expression vector (eg, rpichia Expression Kitj (Invitrogen), pNVIK SP-Q01), and Bacillus subtilis-derived expression vectors (eg, pPL608, pKTH50).
- insect cell-derived expression vector eg, "Bac-to-BAC baculovirus expression systemj (GI BCO BRL), pBacPAK8)
- plant-derived expression Vector eg, ⁇ 1, pMH2
- animal virus-derived expression vector eg, pHSV, pMV, pAdexLcw
- promoters required for expression in cells such as the SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMLV-LTR promoter, EF1 promoter Yuichi (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322), CMV promoter Yuichi, etc.
- Genes that can be distinguished by the gene for selection eg, drug (neomycin, G418, etc.)
- Vectors having such characteristics include, for example, bandits, pDR2, pBK-RSV, pBK-CMV, pOPRSV, pOP13, and the like.
- a DHFR gene complementing the nucleic acid synthesis pathway-deficient CH0 cell is required.
- MTX methotrexate
- SV40 T antigen is expressed.
- An example is a method in which a COS cell having a gene on a chromosome is used to transform with a vector (such as pcD) having an SV40 origin of replication.
- a vector such as pcD
- the replication origin those derived from poliovirus, adenovirus, sipabiloma virus (BPV), etc. can also be used.
- the expression vector should be used as a selection marker for aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, Escherichia coli xanthinguanine phosphoribosyl transferase ( Ecogp t) gene, dihydrofolate reductase (dhfr) gene and the like.
- APH aminoglycoside transferase
- TK thymidine kinase
- Ecogp t Escherichia coli xanthinguanine phosphoribosyl transferase
- dhfr dihydrofolate reductase
- the MA of the present invention is incorporated into an appropriate vector, and the retrovirus method, ribosome method, cationic liposome method, adenovirus method, and the like are used to express the DNA in vivo.
- the vector used include an adenovirus vector (eg, pAdexlcw) and a retrovirus vector.
- the present invention also relates to a host cell into which the vector of the present invention has been introduced.
- the host cell into which the vector of the present invention is introduced is not particularly limited, and for example, Escherichia coli and various animal cells can be used.
- the host cell of the present invention can be used, for example, as a production system for producing or expressing the protein of the present invention.
- Production systems for protein production include in vitro and in vivo production systems. Examples of in vitro production systems include production systems using eukaryotic cells and production systems using prokaryotic cells.
- animal cells for example, animal cells, animal cells, and fungal cells can be used as hosts.
- animal cells mammalian cells, for example, CHO (J. Exp. Med.
- CH0 cells include dhfr-CHO (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO K-l, which are CH0 cells lacking the DHFR gene.
- the vector can be introduced into a host cell by, for example, the calcium phosphate method, the DEAE dextran method, the method using the cationic ribosome D0TAP (Boehringer Mannheim), the electoral poration method, or the Lipofexion method. is there.
- Nicotiana tabacum As plant cells, for example, cells derived from Nicotiana tabacum (Nicotiana tabacum) are known as protein production systems, which may be callus cultured.
- Fungal cells include yeast, for example, Saccharomyces ces, for example, Saccharomyces cerevisiae, filamentous fungi, for example, Aspergillus ⁇ , for example, Aspergillus ger luger It has been known.
- prokaryotic cells there are production systems that ffl bacterial cells. Examples of the bacterial cells include Escherichia coli (E. coli), for example, JM109, DH5 and HB101, and Bacillus subtilis.
- the protein is obtained by transforming these cells with the desired DNA and culturing the transformed cells in vitro.
- the culturing can be performed according to a known method.
- DMEM, MEM, RPM 11640, IMDM can be used as a culture solution of animal cells.
- a serum supplement such as fetal calf serum (FCS) can be used together, or serum-free culture may be performed.
- FCS fetal calf serum
- the pH during culturing is preferably about 6-8. Culture is usually performed at about 30 to 40 ° C for about 15 to 200 hours, and the medium is replaced, aerated, and agitated as necessary.
- examples of a system for producing a protein in vivo include a production system using an animal and a production system using a plant.
- the target DNA is introduced into these animals or plants, and proteins are produced and recovered in the animals or plants.
- the “host” in the present invention includes these animals and plants.
- mammals When using animals, there are production systems using mammals and insects. As mammals, goats, bushes, hidges, mice, and sea lions can be used (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). When a mammal is used, a transgenic animal can be used.
- the target DNA is prepared as a fusion gene with a gene encoding a protein that is specifically produced in milk, such as goat 5-casein.
- the DNA fragment containing the fusion gene is introduced into a goat embryo, and the embryo is transplanted into a female goat.
- the target protein can be obtained from milk produced by the transgenic goat born from the goat that has received the embryo or its progeny.
- Hormones may be used in transgenic goats as appropriate to increase the amount of milk containing proteins produced by transgenic goats (Ebert, KM et al., Bio / Technology (1994) 12, 699). -702).
- silkworms can be used as insects, for example.
- the target protein can be obtained from the body fluid of the silkworm by infecting the silkworm with a baculovirus into which DNA encoding the target protein has been inserted (Susufflu, M. et al., 2003). , Nature (1985) 315, 592-594).
- tobacco when using a plant, for example, tobacco can be used.
- the DNA encoding the protein of interest is introduced into a plant expression vector, for example, pMON530, and this vector is transformed into bacteria such as Agrobacterium tumefaciens. Introduce.
- This bacterium is infected with tobacco, for example, Nicotiana tabacum, and the desired polypeptide can be obtained from the leaves of this tobacco (Julian K. -C. Ma et al., Eur. J. Immunol. (1994) 24, 131-138).
- the protein of the present invention thus obtained can be separated from the inside or outside of the host cell (such as a medium) and purified as a substantially pure and homogeneous protein.
- the separation and purification of the protein may be performed by the separation and purification methods used in ordinary protein purification, and are not limited at all. For example, chromatographic chromatography, filters, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization
- the proteins can be separated and purified by appropriately selecting and combining them.
- chromatography examples include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographys can be performed using liquid phase chromatography, for example, liquid phase chromatography such as HPLC and FPLC.
- the present invention also includes highly purified proteins using these purification methods.
- the protein can be arbitrarily modified or partially removed by reacting the protein with an appropriate protein modification enzyme before or after purification.
- the present invention also relates to an antibody that binds to the protein of the present invention.
- the form of the antibody of the present invention is not particularly limited, and includes a monoclonal antibody in addition to a polyclonal antibody. Also included are antisera obtained by immunizing immunized animals such as rabbits with the protein of the present invention, polyclonal antibodies and monoclonal antibodies of all classes, as well as human antibodies and humanized antibodies obtained by genetic recombination.
- the protein of the present invention used as a sensitizing antigen for obtaining an antibody is not limited to the animal species from which it is derived, but is preferably a protein derived from a mammal, for example, a human, a mouse or a rat. Is preferred. Human-derived proteins can be obtained using the gene sequences or amino acid sequences set forth herein.
- the protein used as the sensitizing antigen may be a complete protein or a partial peptide of the protein.
- partial peptides of the protein include amino (N) terminal fragments and protein (C) terminal fragments of proteins.
- antibody refers to an antibody that reacts with the full length or fragment of a protein.
- a gene encoding the protein of the present invention or a fragment thereof is inserted into a known expression vector system, and the vector is used to transform a host cell described in the present specification.
- a fragment thereof may be obtained by a known method, and these may be used as a sensitizing antigen.
- a cell expressing the protein, a lysate thereof, or a chemically synthesized protein of the present invention may be used as the sensitizing antigen.
- the mammal to be immunized with the sensitizing antigen is not particularly limited, but is preferably selected in consideration of compatibility with the parent cells used for cell fusion. Teeth, egrets, and primates are used.
- mice for example, mice, rats, hamsters and the like are used.
- a heronoid animal for example, a heron is used.
- monkeys are used as primates.
- monkeys of the lower nose for example, cynomolgus monkeys, rhesus monkeys, baboons, chimpanzees, etc. are used.
- Immunization of an animal with a sensitizing antigen is performed according to a known method.
- a sensitizing antigen is injected intraperitoneally or subcutaneously into a mammal.
- the sensitizing antigen is diluted and suspended in an appropriate amount with PBS (Phosphate-Buffered Sine) or physiological saline, and then mixed with an appropriate amount of a normal adjuvant, for example, Freund's complete adjuvant, if desired. After emulsification, it is administered to mammals. Thereafter, it is preferable to administer the sensitizing antigen mixed with an appropriate amount of Freund's incomplete adjuvant several times every 4 to 21 days.
- a suitable carrier can be used at the time of immunization with the sensitizing antigen. Immunization is performed in this manner, and an increase in the level of the desired antibody in the serum is confirmed by a conventional method.
- the blood of a mammal sensitized with the antigen is taken out.
- the serum is separated from the blood by a known method.
- a serum containing the polyclonal antibody may be used.
- a fraction containing the polyclonal antibody may be further isolated from this serum and used. For example, using an affinity column to which the protein of the present invention has been coupled, a fraction that recognizes only the protein of the present invention is obtained, and this fraction is further purified using a protein A or protein G column.
- immunoglobulin G or M can be prepared.
- the immune cells may be removed from the mammal and subjected to cell fusion.
- preferred immune cells used for cell fusion include spleen cells.
- the other parent cell to be fused with the immune cell is preferably a mammalian myeloma cell, and more preferably a myeloma cell that has acquired the properties for selecting fused cells by a drug.
- Cell fusion between the immune cells and myeloma cells is basically performed by a known method, for example, the method of Milstein et al. (Galfre, G. and Milstein, C, Methods Enzymol. (1981) 73, 3-46). It can be performed according to it.
- the hybridoma obtained by cell fusion is selected by culturing it in a normal selective culture medium, for example, a HAT culture medium (a culture medium containing hypoxanthine, aminopterin and thymidine). Culturing in the HAT culture solution is continued for a time sufficient to kill cells other than the target hybridoma (non-fused cells), usually for several days to several weeks. Next, a conventional limiting dilution method is performed to screen and clone a hybridoma producing the desired antibody.
- a normal selective culture medium for example, a HAT culture medium (a culture medium containing hypoxanthine, aminopterin and thymidine). Culturing in the HAT culture solution is continued for a time sufficient to kill cells other than the target hybridoma (non-fused cells), usually for several days to several weeks.
- a conventional limiting dilution method is performed to screen and clone a hybridoma producing the desired antibody.
- a human lymphocyte for example, a human lymphocyte infected with an EB virus is sensitized in vitro with a protein, a protein-expressing cell or a lysate thereof
- the sensitized lymphocytes can be fused with human-derived myeloma cells having permanent cleavage ability, for example, U266, to obtain a hybridoma that produces a desired human antibody having binding activity to a protein (Japanese Patent Laid-Open No. -17688 ⁇ gazette) o
- the obtained hybridoma was transplanted into the peritoneal cavity of a mouse, ascites was recovered from the mouse, and the obtained monoclonal antibody was subjected to, for example, ammonium sulfate precipitation, a protein and protein G column, DEAE ion exchange chromatography, and the present invention. It can be prepared by purifying the protein using an affinity column to which the protein is coupled.
- the antibody of the present invention is used for purification and detection of the protein of the present invention. In addition, it is a candidate for an agonist and an engonist of the protein of the present invention. It is also conceivable to apply this antibody to antibody therapy for diseases involving proteins according to the present invention.
- a human antibody ⁇ a human antibody is preferable in order to reduce immunogenicity.
- a transgenic animal having a human antibody gene repertoire was immunized with a protein serving as an antigen, protein-expressing cells or a lysate thereof to obtain antibody-producing cells, which were fused with myeloma cells.
- a human antibody to a protein can be obtained using the hybridoma (see International Publication Nos. W092--03918, W093-2227, W094-02602, W094-25585, W096-33735, and W096-34096).
- cells in which immune cells such as sensitized lymphocytes that produce antibodies are immortalized with oncogenes may be used.
- the thus obtained monoclonal antibody can also be obtained as a recombinant antibody produced using a genetic recombination technique (for example, Borrebaeck, CAK and Larrick, JW, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the
- Recombinant antibodies are produced by cloning the DNA encoding them from immunized cells such as hybridomas or sensitized lymphocytes producing the antibodies, incorporating the DNA into an appropriate vector, and introducing it into a host.
- the present invention includes this recombinant antibody.
- the antibody of the present invention may be an antibody fragment or a modified antibody thereof as long as it binds to the protein of the present invention.
- antibody fragments include Fab, F (ab ') 2, Fv or single chain Fv (scFv) in which Fv of H chain and L chain are linked by an appropriate linker.
- the antibody is treated with an enzyme, for example, papain or pepsin, to generate an antibody fragment, or a gene encoding these antibody fragments is constructed and introduced into an expression vector.
- an enzyme for example, papain or pepsin
- a gene encoding these antibody fragments is constructed and introduced into an expression vector.
- the modified antibody an antibody bound to various molecules such as polyethylene glycol (PEG) can be used.
- PEG polyethylene glycol
- the “antibody” of the present invention also includes these modified antibodies. In order to obtain such a modified antibody, it can be obtained by subjecting the obtained body to chemical modification. These methods are already established in this field.
- the antibody of the present invention can be used as a chimeric antibody composed of a variable region derived from a non-human antibody and a constant region derived from a human antibody, or a CDR derived from a non-human antibody (complementarity determining region) using known techniques. It can be obtained as a humanized antibody composed of human antibody-derived FR (framework region) and constant region.
- the antibody obtained as described above can be purified to homogeneity.
- the separation and purification of the antibody used in the present invention may be performed by the separation and purification methods used for ordinary proteins. For example, if chromatography chromatography columns such as affinity chromatography, filtration, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, etc. are appropriately selected and combined, Antibody can be separated and purified (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988).
- the concentration of the antibody obtained above can be measured by absorbance measurement, enzyme-linked immunosorbent assay (ELISA), or the like.
- Columns used for affinity chromatography include a protein A column and a protein G column.
- a protein A column examples include Hyper D, POROS, Sepharose F.F. (Pharmacia) and the like.
- Chromatography other than affinity chromatography includes, for example, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manua 1. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 199 6). These chromatographys can be performed using liquid phase chromatography such as HPLC and FPLC.
- Methods for measuring the antigen-binding activity of the antibody of the present invention include, for example, measurement of absorbance, enzyme-linked immunosorbent assay (ELISA), EIA (enzyme-linked immunosorbent assay), and RIA (enzyme-linked immunosorbent assay). (Radioimmunoassay) or a fluorescent antibody method.
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme-linked immunosorbent assay
- RIA enzyme-linked immunosorbent assay
- a secondary antibody that recognizes an enzyme for example, an antibody labeled with alkaline phosphatase, etc.
- an enzyme substrate such as P-nitrophenyl phosphate
- the antigen binding activity can be evaluated.
- a fragment of the protein for example, a C-terminal fragment or an N-terminal fragment thereof may be used.
- BIAcore Pharmacia
- the antibody of the present invention is brought into contact with a sample expected to contain the protein of the present invention contained in the sample, and an immune complex of the antibody and the protein is detected or measured.
- the method for detecting or measuring the protein of the present invention can be carried out. Since the protein detection or measurement method of the present invention can specifically detect or measure protein, it is useful for various experiments and the like using proteins.
- the present invention also relates to a nucleotide that hybridizes to the DNA encoding the protein of SEQ ID NO: 2 (SEQ ID NO: 1) or a complementary strand thereof and has a chain length of at least 15 bases.
- the nucleotide of the present invention specifically hybridizes to DNA encoding the protein described in SEQ ID NO: 2 (SEQ ID NO: 1) or its complementary strand.
- SEQ ID NO: 2 SEQ ID NO: 1
- the term “specifically hybridize” as used herein means that under normal hybridization conditions, preferably under stringent hybridization conditions, cross-hybridization with DNA encoding other proteins is significant. Means not to occur.
- Such nucleotides include probes or primers, nucleotides or nucleotide derivatives capable of specifically hybridizing with DNA encoding the protein of the present invention or DNA complementary to the DNA (for example, antisense oligonucleotide ribozyme, Encoding DNA). Such nucleotides can also be used for producing a DNA chip.
- the present invention includes, for example, an antisense oligonucleotide that hybridizes at any position in the nucleotide sequence of SEQ ID NO: 1.
- This antisense oligonucleotide is preferably an antisense oligonucleotide for at least 15 consecutive nucleotides in the base sequence of SEQ ID NO: 1. More preferably, the antisense oligonucleotide described above, wherein at least 15 or more consecutive nucleotides include a translation start codon.
- antisense oligonucleotide derivatives and modifications thereof can be used. Examples of such modifications include lower alkylphosphonate modification such as methylphosphonate type or ethylphosphonate type, phosphorothioate modification, and phosphoramidite modification.
- the term “antisense oligonucleotide” includes not only those in which all nucleotides corresponding to nucleotides constituting a predetermined region of DNA or mRNA are complementary, and those in which DNA or mRNA and the oligonucleotide are represented by SEQ ID NO: 1. As long as it can specifically hybridize to the nucleotide sequence shown in (1), there may be a mismatch of one or more nucleotides.
- nucleotides have at least 70%, preferably at least 80 °, more preferably 90%, even more preferably 95% or more nucleotide sequence homology in at least 15 contiguous nucleotide sequence regions.
- the algorithm for determining homology may use the algorithm described in this specification.
- Such a DNA is useful as a probe for detecting or isolating a DNA encoding the protein of the present invention, or as a primer for amplifying, as described in Examples below.
- the antisense oligonucleotide derivative of the present invention acts on cells producing the protein of the present invention to inhibit transcription or translation of the protein or to degrade mRNA by binding to DNA or mRNA encoding the protein. Or by suppressing the expression of the protein of the present invention, thereby effectively suppressing the action of the protein of the present invention.
- the antisense oligonucleotide derivative of the present invention can be mixed with a suitable base material which is inactive against the derivative to be used as an external preparation such as a coating agent or a knocking agent.
- the antisense oligonucleotide derivative of the present invention is applied directly to an affected area of a patient, or is applied to a patient so as to be able to reach the affected area as a result of intravenous administration or the like.
- ribosome, poly-L-lysine, lipid, cholesterol, lipofectin or a derivative thereof can be mentioned.
- the dosage of the antisense oligonucleotide derivative of the present invention can be appropriately adjusted according to the condition of the patient, and a preferred amount can be used. For example, it can be administered in the range of 0.1 to 100 mg / kg, preferably in the range of 0.1 to 50 mg / kg.
- the antisense oligonucleotide of the present invention inhibits the expression of the protein of the present invention, and is therefore useful in suppressing the biological activity of the protein of the present invention.
- the expression inhibitor ⁇ containing the antisense oligonucleotide of the present invention is useful in that it can suppress the biological activity of the protein of the present invention.
- the present invention provides a method for screening a compound that binds to the protein of the present invention, using the protein of the present invention, and a compound that can be isolated by the screening method (for example, a receptor, an agonist, and an angelist). About.
- the protein of the present invention used for the screening may be any of a recombinant type, a natural type and a partial peptide.
- One embodiment of this screening method includes: (a) a step of bringing a test sample into contact with the protein of the present invention or a partial peptide thereof; (b) a compound having an activity of binding to the protein of the present invention or a partial peptide thereof. Selecting.
- the test sample is not particularly limited, and includes, for example, cell extract, cell culture supernatant, fermentation microorganism product, marine organism extract, plant extract, produced or crude protein, peptide, non-peptide Compounds, synthetic low molecular weight compounds, and natural compounds.
- the protein of the present invention to be brought into contact with a test sample is expressed on a cell membrane, for example, as a purified protein, as a soluble protein, in a form bound to a carrier, or as a fusion protein with another protein. As a form, it can be brought into contact with a test sample as a membrane fraction.
- a method for screening a protein that binds to the protein using the protein of the present invention many methods known to those skilled in the art can be used. Such screening can be performed, for example, by immunoprecipitation. Ingredient Physically, it can be performed as follows. By inserting the gene encoding the protein of the present invention into a vector for expressing a foreign gene such as pSV2neo, pcDNAI, or pCD8, the gene is expressed in animal cells or the like. SV40 early promoter (Rigby In Williamson [ed.), Genetic Engineering, Vol. 3. Academic Press, London, p. 83-141 (1982)), EF-1a promoter (K im et al.
- CAG promoter Niwa et al. Gene 108, p.193-200 (1991)
- RSV LTR promoter Cullen Methods in Enzymology 152, p.684-704) (1987), SR a promoter (Takebe et al. Mol. Cell. Biol. 8, p.466 (1988)), CMV immediate early promoter (Seed and Aruffo Proc. Natl. Acad. Sci. USA 84, p. 3365-3369 (1987)), SV40 late promoter (Gheysen and Fiers J. Mol. Appl. Genet.
- HSV TK promoter can be used to express a foreign gene by introducing the gene into animal cells. Is based on the electroporation method (Chu, G. et al. Nucl. Acid Res, 15, 1311-1326 (1987)), Calcium phosphate method (Chen, C and Okayama, H. Mol. Cell. Biol. 7, 2745-2752 (1987)), DEAE dextran method (Lopata, MA et al. Nucl. Acids Res. 12, 5707-5717)
- the protein of the present invention can be used as a fusion protein having a recognition site of the monoclonal antibody. It can be expressed.
- the ebitope-antibody system to be used the ⁇ version can be used (Experimental Medicine 13, 85-90 (1995)).
- vectors that can express fusion proteins with galactosidase, maltose binding protein, glutathione S-transferase, green fluorescent protein (GFP), and the like are commercially available.
- polyhistidine His-tag
- influenza agglutinin HA human c-myc
- FLAG Vesicular stomatitis virus glycoprotein
- VSV-GP Vesicular stomatitis virus glycoprotein
- T7-tag human simple virus Epitopes such as viral glycoproteins (HSV-tags) and E-tags (epitopes on monoclonal phages) and monoclonal antibodies that recognize them can be used to screen for proteins that bind to the protein of the present invention.
- Epitope-available as an antibody system Example 13 85-90 (1995)).
- an immune complex is formed by adding these antibodies to a cell lysate prepared using an appropriate surfactant.
- This immune complex comprises the protein of the present invention, a protein capable of binding thereto, and an antibody.
- immunoprecipitation can be performed using an antibody against the protein of the present invention.
- Antibodies against the protein of the present invention can be obtained, for example, by introducing a gene encoding the protein of the present invention into an appropriate E. coli expression vector and expressing it in E. coli, purifying the expressed protein, It can be prepared by immunizing rats, goats, and chickens. Alternatively, it can be prepared by immunizing the above animal with the synthesized partial peptide of the protein of the present invention.
- the immune complex can be precipitated using Protein A Sepharose or Protein G Sepharose.
- the protein of the present invention when prepared as a fusion protein with an epitope such as GST, for example, it specifically binds to such an epitope such as glucanthione-Sepharose 4B.
- An immunocomplex can be formed using the substance that binds, similarly to the case where an antibody against the protein of the present invention is used.
- SDS-PAGE is generally used for the analysis of immunoprecipitated proteins.
- the protein bound to the protein of the present invention is generally a radioisotope, since it is difficult to detect the protein by ordinary staining methods such as Coomassie staining and silver staining : i cells were cultured in a culture solution containing "'S- Mechionin and 35 S- system-in, labeling proteins in said cell, which can improve the detection sensitivity by detecting.
- molecular weight of the protein Once this is known, the target protein can be purified directly from the SDS-polyacrylamide gel and its sequence determined.
- Examples of a method for isolating a protein that binds to the protein using the protein of the present invention include, for example, a West Western blotting method (Skolnik,
- phage vectors human gtll from cells, tissues, and organs (eg, hearts, lungs, livers, kidneys, and other organs and embryos) that are expected to express the binding protein that binds to the protein of the present invention.
- ZAP, etc. express this on LB-agarose, immobilize the expressed protein on a filter, and purify and purify the labeled protein of the present invention with the above-mentioned filter.
- the plaque expressing the protein bound to the protein of the present invention may be detected by labeling.
- Examples of the method for labeling the protein of the present invention include a method utilizing the binding property of biotin and avidin, a protein of the present invention or a peptide fused to the protein of the present invention.
- Examples include a method using an antibody that specifically binds to a polypeptide (for example, GST), a method using a radioisotope, a method using fluorescence, and the like.
- a 2-hybrid system using cells (“MATCHMAKER Two-Hybrid Systemj”, “Mammalian MATCHMA KER Two-Hybrid Assay Kitj”, “MATC image ER One-Hybrid Systemj”) (Both CI ontech), “HybriZAP Two-Hybrid Vector Systemj (Stratagene), Cyto Trap two-hybrid system (Stratagene), Literature Factory Dalton S, and Treisman R (1992) Characterization of SAP-1, a protein recruited by serum response f actor to the c-fos serum response element.Cell 68, 597-612, reference Fie Ids, S., and Sternglanz, R., Trends.Genet. (1994) 10, 286-292 j )).
- the protein of the present invention must be fused with the SRF DNA binding region or GAL4 DNA binding region and expressed in yeast cells to express the protein that binds to the protein of the present invention.
- the repo overnight gene besides the HI S3 gene, the Ade2 gene, LacZ gene, CAT gene, luciferase 1 gene, PAI-1 (Plasminogen activator inhibitor typel) gene and the like can be used.
- Screening for a compound that binds to the protein of the present invention can also be performed using affinity chromatography.
- the protein of the present invention is immobilized on a carrier of an affinity column, and a protein that binds to the protein of the present invention.
- a test sample that is expected to express protein is applied.
- examples of the test sample include a cell extract, a cell lysate, and the like. After applying the test sample, the column is washed, and the protein bound to the protein of the present invention can be prepared.
- the obtained protein is analyzed for its amino acid sequence, oligo DNA is synthesized based on the amino acid sequence, and a cDNA library is screened using the DNA as a probe to obtain a DNA encoding the protein.
- a biosensor utilizing the surface plasmon resonance phenomenon can be used as a means for detecting or measuring the bound compound.
- a biosensor utilizing the surface plasmon resonance phenomenon enables real-time monitoring of the interaction between the protein of the present invention and a test compound as a surface plasmon resonance signal using a small amount of protein and without labeling. (Eg, BIAcore, Pharmacia). Therefore, it is possible to evaluate the binding between the protein of the present invention and a test compound by using a biosensor such as BIAcore.
- the method for isolating not only proteins but also compounds (including agonists and angonists) that bind to the protein of the present invention includes, for example, immobilized proteins of the present invention, synthetic compounds, and natural product banks. Or a random phage peptide display library, and a method for screening for a molecule that binds to the protein of the present invention, or a method for screening using combinatorial chemistry technology using hysteresis (Wrighton NC et al., Science (U.
- Compounds that can be isolated by screening are candidates for drugs for promoting or inhibiting the activity of the protein of the present invention, and can be applied to the treatment of diseases caused by abnormal expression or function of the protein of the present invention.
- Screening of the invention A substance obtained by using the screening method of the present invention, which partially converts the structure of the compound having the activity of binding to the protein of the present invention by addition, deletion and / or substitution, can also be obtained by using the screening method of the present invention. Included in the resulting compound.
- the compound obtained by the screening method of the present invention and the protein of the present invention may be used for humans or mammals, for example, mice, rats, guinea pigs, rabbits, chicks, cats, dogs, higgies, bushus, monkeys, monkeys.
- a medicament for baboons and chimpanzees it is possible to administer the isolated compound itself to the patient in addition to directly administering the isolated compound to the patient by a known pharmaceutical method.
- a sugar-coated tablet, capsule, elixir, microcapsule, orally, or aseptic solution or suspension in water or other pharmaceutically acceptable liquids Can be used parenterally in the form of injections.
- pharmacologically acceptable carriers or vehicles specifically, sterile water or saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives It can be formulated by combining as appropriate with agents, binders, etc., and mixing in the unit dosage form generally required for pharmaceutical practice.
- the amount of the active ingredient in these preparations is such that an appropriate dose in the specified range can be obtained.
- Additives that can be incorporated into tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum, acacia, excipients such as crystalline cellulose, corn starch, gelatin, and alginic acid.
- Useful bulking agents such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and flavoring agents such as peppermint, cocoa oil or cherry.
- a liquid carrier such as oils and fats can be further contained in the above-mentioned materials.
- Sterile compositions for injection can be formulated according to normal pharmaceutical practice using a vehicle such as distilled water for injection.
- Aqueous solutions for injection include, for example, saline, isotonic solutions containing dextrose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, sodium chloride And suitable solubilizers, for example, alcohols, specifically, ethanol, polyalcohols, for example, propylene glycol, polyethylene glycol, nonionic surfactants, for example, polysorbate 80 (TM), HC0-50 May be used in combination.
- dextrose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, sodium chloride
- solubilizers for example, alcohols, specifically, ethanol, polyalcohols, for example, propylene glycol, polyethylene glycol, nonionic surfactants, for example, polysorbate 80 (TM), HC0-50 May be used in combination.
- the oily liquid includes sesame oil and soybean oil, and may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizer. It may also be combined with a buffer, for example, a phosphate buffer, a sodium acetate buffer, a soothing agent, for example, proforce hydrochloride, a stable agent, for example, benzyl alcohol, phenol, or an antioxidant.
- a buffer for example, a phosphate buffer, a sodium acetate buffer, a soothing agent, for example, proforce hydrochloride, a stable agent, for example, benzyl alcohol, phenol, or an antioxidant.
- the prepared injection solution is usually filled into an appropriate ampoule.
- Administration to patients can be performed, for example, by intraarterial injection, intravenous injection, subcutaneous injection, etc., or intranasally, transbronchially, intramuscularly, transdermally, or orally by a method known to those skilled in the art. It can do better.
- the dose varies depending on the weight and age of the patient, the administration method, and the like, but those skilled in the art can appropriately select an appropriate dose.
- the compound can be encoded by DNA
- the DNA may be incorporated into a gene therapy vector to perform gene therapy.
- the dose and the administration method vary depending on the patient's body weight, age, symptoms and the like, but can be appropriately selected by those skilled in the art.
- the dose of the protein of the present invention may vary depending on the administration target, organ organs, symptoms, and administration method.
- an adult in the case of an injection, an adult (assuming a body weight of 60 kg) usually has 1 dose. It is considered to be about 100 ⁇ g to 20m per day.
- the dose of a compound that binds to the protein of the present invention or a compound that inhibits the activity of the protein of the present invention varies depending on the condition.
- oral administration in general, in adults (with a body weight of 60 kg), About 0.1 to 100 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg per day.
- the single dose varies depending on the administration target, target organ, symptoms, and administration method.
- injection II it is usually used for adults (with a body weight of 60 kg) per day.
- the dose can be administered in terms of the amount converted per 60 kg body weight or the amount converted per body surface area.
- FIG. 1 shows the homology between clone 106 (upper) and the amino acids encoded by the Drosophila twisted gastrulation (TSG) gene (lower). Asterisks (*) were given to identical amino acid sequences, and dots (.) Were given to similar amino acid sequences. Gaps were supplemented by bars. BEST MODE FOR CARRYING OUT THE INVENTION
- the AGM region was collected from the 11.5 day mouse embryo, and polyA (+) RNA was prepared using Fast Track (Invitrogen). Double-stranded cDNA was synthesized using random primers of the Superscript Choice System (GIBCO BRL). After blunt-ending the cDNA, a BstX I adapter (Invitrogen) was added, and a cDNA of 400 bp or more was fractionated using a SizeSep 400 Spun Column (Pharmacia).
- the mixture was mixed with pMXGM (-) v-mpl M2 (see Japanese Patent Application No. 9-324912) treated with BstXI (TAKARA) and ligated with T4 DNA ligase.
- This was introduced into Escherichia coli DHIOB (GIBCO BRL) by electroporation using a Gene Pulser (Bio Rad), cultured overnight, and then a cDNA library was purified using a JETstar column (GEN0MED).
- a cDNA library was transfected into B0SC23 (Proc. Natl. Acad. Sci. USA, 90, 8392-8396, 1993), a packaging cell, using LipofectAMINE (LIFE TECHNOLOGIES).
- B0SC23 with 10% fetal serum FCS, JRH BIOS 35
- DMEM LIFE TECHNOLOGIES
- IL-3 Mouse interleukin-3 (IL-3) and 10 ⁇ g / ml hexadimethrine bromide were added to the culture supernatant containing the recombinant virus, and Ba / F3 was suspended in the suspension and infected. After 24 hours after infection, the cells were washed three times with PBS and cultured with RPMI 1640 containing 10% FCS (LIFE TECHNOLOGIES).
- DNA was extracted from clones grown in the absence of IL-3, and primers were set so as to sandwich the cDNA insertion site, 5'-gggggTggACCATCCTCTA-3 '(SEQ ID NO: 3) and 5, -CgCgCAgCTgTAAACggTAg-3' PCR was performed using (SEQ ID NO: 4) to recover a cDNA fragment.
- PCR 500 ng DNA, 500 pM each primer, TaKaRaLA Taq (TAKARA) 2.5 units, 2.5 mM MgCl, 0.3 mM dNTPs and 50 ⁇ 1 of the reaction solution containing the buffer attached to the enzyme GeneAmpPCR System2400 (Perkin Elmer) Under the following conditions.
- the TSG gene of Drosophi la is considered to be one of the dorsal determinants of the embryo, and mutation of this gene prevents the differentiation of only the mesodermal dorsal midline cell.
- Decapentaplegic (DPP) which is also a dorsal determinant and is thought to interact with the TSG gene, is markedly different in that dorsal dorsal differentiation is affected.
- a cDNA library of mouse embryo 11.5 was synthesized using oligo dT primer in the same manner as in Example 1, and the cDNA fragment was screened with a probe.
- One 2 ⁇ g of the cDNA library was added to 50 ⁇ l of DH5 alpha (GIBCO BRL) and left at ice temperature for 30 minutes. After applying a heat shock at 42 ° C for 30 seconds, the mixture was kept at ice temperature for about 2 minutes, and S0C was added at 300/1, followed by culturing at 37 ° C for 30 minutes.
- Hybridization was performed according to the following procedure. First, the membrane was prehybridized in a hybridization buffer (50% formamide, 4.5% Dextran Sulfate, O. lmg / ml salmon sperm DNA, 6X SSC, 1% SDS) for 2 hours at 42 ° C. I did. Using Prime-It (Stratagene), 25 ng of clone 106 DNA as a probe was RI-labeled, heat-denatured, and then added to a hybridization buffer and left overnight.
- a hybridization buffer 50% formamide, 4.5% Dextran Sulfate, O. lmg / ml salmon sperm DNA, 6X SSC, 1% SDS
- Washing of the membrane was performed in two stages. After washing with a washing buffer (2 x SSC, 0.1% SDS) at 42 ° C for 10 minutes, the plate was washed with a washing buffer (O.l x SSC 0.13 ⁇ 4SDS) at 55 ° C for 30 minutes. The membrane thus washed was adhered to an X-ray film, exposed to light at -80 ° C, and developed.
- a washing buffer (2 x SSC, 0.1% SDS
- One clone was obtained by the above procedure. It was a cDNA with a base sequence of 3986 bp, and an open reading frame (87-752) encoding 222 amino acids was recognized. Was. 1-24 amino acids are deduced to be the signal sequence.
- the nucleotide sequence of the cDNA is shown in SEQ ID NO: 1, and the encoded amino acid sequence is shown in SEQ ID NO: 2.
- the proteins and genes found in the present invention may be the mouse counterparts of the Drosophila TSG gene, suggesting that they are functionally similar. By examining the role of the proteins and genes of the present invention in embryo development, they can contribute to elucidation of the mechanisms of differentiation and bone formation associated with the development of hematopoietic stem cells. It is also useful as a tool for developing therapeutics for immune and hematopoietic disorders and osteogenic disorders.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00956961A EP1215284A4 (en) | 1999-09-06 | 2000-09-06 | TSG TYPE GENE |
AU68719/00A AU6871900A (en) | 1999-09-06 | 2000-09-06 | Tsg-like gene |
US10/092,925 US6890735B2 (en) | 1999-09-06 | 2002-03-06 | TSG-like gene |
US11/079,947 US20050164280A1 (en) | 1999-09-06 | 2005-03-15 | TSG-like gene |
US11/940,927 US20090197317A1 (en) | 1999-09-06 | 2007-11-15 | TSG-Like Gene |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/252190 | 1999-09-06 | ||
JP25219099 | 1999-09-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/092,925 Continuation-In-Part US6890735B2 (en) | 1999-09-06 | 2002-03-06 | TSG-like gene |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001018200A1 true WO2001018200A1 (fr) | 2001-03-15 |
Family
ID=17233761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/006050 WO2001018200A1 (fr) | 1999-09-06 | 2000-09-06 | Gene de type tsg |
Country Status (4)
Country | Link |
---|---|
US (3) | US6890735B2 (ja) |
EP (1) | EP1215284A4 (ja) |
AU (1) | AU6871900A (ja) |
WO (1) | WO2001018200A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004074483A1 (ja) * | 2003-02-20 | 2006-06-01 | 哲哉 野阪 | Tsg遺伝子ノックアウト動物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317688A (ja) | 1986-03-28 | 1988-01-25 | Kimiyoshi Tsuji | ヒト―ヒトハイブリドーマの製造法 |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH09324912A (ja) | 1996-06-05 | 1997-12-16 | Ishikawajima Harima Heavy Ind Co Ltd | 灰溶融炉 |
WO1998046641A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Novel polypeptides within the growth factor superfamily |
WO1999038976A2 (en) * | 1998-01-29 | 1999-08-05 | Incyte Pharmaceuticals, Inc. | Human growth factor homologs |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US46413A (en) * | 1865-02-14 | Improvement in graduated dumb-bells | ||
US38468A (en) * | 1863-05-12 | Photographic-printing frame | ||
US108138A (en) * | 1870-10-11 | Improvement in compositions for welding, puddling, and brazing metals | ||
US127712A (en) * | 1872-06-11 | Improvement in rock-drilling machines | ||
CA2249251A1 (en) | 1996-03-20 | 1997-09-25 | Human Genome Sciences, Inc. | Human cytokine polypeptide |
AU5369296A (en) | 1996-03-20 | 1997-10-10 | Human Genome Sciences, Inc. | Human cytokine polypeptide |
US20020127712A1 (en) | 2000-06-29 | 2002-09-12 | Brennan Thomas J. | Transgenic mice containing anaphylatoxin C3a gene disruptions |
US20020108138A1 (en) | 2000-06-29 | 2002-08-08 | Catherine Guenther | Transgenic mice containing RORgamma gene disruptions |
JP2004524002A (ja) | 2000-06-29 | 2004-08-12 | デルタジェン インコーポレイテッド | 標的化された遺伝子破壊を含むトランスジェニックマウス |
US20020038468A1 (en) | 2000-06-29 | 2002-03-28 | Leviten Michael W. | Transgenic mice containing chordin gene disruptions |
US6784335B2 (en) | 2000-06-29 | 2004-08-31 | Deltagen, Inc. | Transgenic mice containing BMP gene disruptions |
-
2000
- 2000-09-06 AU AU68719/00A patent/AU6871900A/en not_active Abandoned
- 2000-09-06 EP EP00956961A patent/EP1215284A4/en not_active Withdrawn
- 2000-09-06 WO PCT/JP2000/006050 patent/WO2001018200A1/ja active Application Filing
-
2002
- 2002-03-06 US US10/092,925 patent/US6890735B2/en not_active Expired - Fee Related
-
2005
- 2005-03-15 US US11/079,947 patent/US20050164280A1/en not_active Abandoned
-
2007
- 2007-11-15 US US11/940,927 patent/US20090197317A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317688A (ja) | 1986-03-28 | 1988-01-25 | Kimiyoshi Tsuji | ヒト―ヒトハイブリドーマの製造法 |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH09324912A (ja) | 1996-06-05 | 1997-12-16 | Ishikawajima Harima Heavy Ind Co Ltd | 灰溶融炉 |
WO1998046641A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Novel polypeptides within the growth factor superfamily |
WO1999038976A2 (en) * | 1998-01-29 | 1999-08-05 | Incyte Pharmaceuticals, Inc. | Human growth factor homologs |
Non-Patent Citations (63)
Title |
---|
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Genetic Engineering", vol. 3, 1982, ACADEMIC PRESS, pages: 83 - 141 |
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS |
BELYAVSKY A. ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 2919 - 2932 |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
BETTER M.; HORWITZ A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496 |
BIRD R. E.; WALKER B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137 |
CHEN, C.; OKAYAMA, H., MOL. CELL. BIOL., vol. 7, 1987, pages 2745 - 2752 |
CHIRGWIN J. M. ET AL., BIOCHEMISTRY, vol. 18, 1979, pages 5294 - 5299 |
CHOMCZYNSKI P.; SACCHI N., ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159 |
CHU, G. ET AL., NUCL. ACID RES., vol. 15, 1987, pages 1311 - 1326 |
CO M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976 |
CULLEN, METHODS IN ENZYMOLOGY, vol. 152, 1987, pages 684 - 704 |
DALBADIE-MCFARLAND G. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 79, 1982, pages 6409 - 6413 |
DALTON, S.; TREISMAN, R.: "Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element", CELL, vol. 68, 1992, pages 597 - 612, XP023884472, DOI: doi:10.1016/0092-8674(92)90194-H |
DERIJARD, B., CELL, vol. 7, 1994, pages 1025 - 1037 |
EBERT K.M. ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702 |
FASEB J., vol. 6, 1992, pages 2422 - 2427 |
FIELDS, S.; STERNGLANZ, R., TRENDS. GENET., vol. 10, 1994, pages 286 - 292 |
FROHMAN M. A. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 8998 - 9002 |
GALFRE G.; MILSTEIN C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
GHEYSEN; FIERS, J. MOL. APPL. GENET., vol. 1, 1982, pages 385 - 394 |
GRANTHAM R. ET AL., NUCLEIC ACIDS RES., vol. 9, 1981, pages 43 - 74 |
HARLOW, E.; LANE, D.: "Antibodies", 1988, COLD SPRING HARBOR LABORATORY, pages: 511 - 552 |
HASHIMOTO-GOTOH ET AL., GENE, vol. 152, 1995, pages 271 - 275 |
HOGAN, J.C. JR., NATURE (ENGLAND), vol. 384, 7 November 1996 (1996-11-07), pages 17 - 19 |
HOPP, T.P. ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210 |
HUSTON J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883 |
JIKKEN IGAKU, EXPERIMENTAL MEDICINE, vol. 13, 1995, pages 85 - 90 |
JULIAN K. -C. MA ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 131 - 138 |
KAUFMAN ET AL., MOL. CELL. BIOL., vol. 9, 1989, pages 946 |
KIM ET AL., GENE, vol. 91, 1990, pages 217 - 223 |
KRAMER W; FRITZ HJ, METHODS ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KRAMER,W ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KUNKEL, METHODS ENZYMOL., vol. 85, 1988, pages 2763 - 2766 |
KUNKEL, TA, PROC NATL ACAD SCI U S A., vol. 82, 1985, pages 488 - 492 |
LAMB, B. T. ET AL., NATURE GENETICS, vol. 5, 1993, pages 22 - 30 |
LAMOYI E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663 |
LEI, S.P. ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379 |
LOPATA, M. A. ET AL., NUCL. ACIDS RES., vol. 12, 1984, pages 5707 - 5717 |
MARK D.F. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 5662 - 5666 |
MASON E.D. ET AL.: "Dorsal midline fate in drosophila embryos requires twisted gastrulation, a gene encoding a secreted protein related to human connective tissue growth factor", GENES & DEVELOPMENT, vol. 8, no. 13, 1994, pages 1489 - 1401, XP002935179 * |
MASON, E.D. ET AL., GENES AND DEVELOPMENT, vol. 8, pages 1489 - 1501 |
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322 |
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 |
NIWA ET AL., GENE, vol. 108, 1991, pages 193 - 200 |
OELGESCHLAGER, M. ET AL., NATURE, vol. 405, 2000, pages 757 - 763 |
PLUCKTHUN A.; SKERRA A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515 |
RABINDRAN, S. K. ET AL., SCIENCE, vol. 259, 1993, pages 230 - 234 |
ROUSSEAUX J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669 |
SAMBROOK, J. ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS, pages: 9.47 - 9.58 |
SEED; ARUFFO, PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3365 - 3369 |
SKOLNIK, E.Y. ET AL., CELL, vol. 65, 1991, pages 83 - 90 |
SUSSMAN, D. J.; MILMAN, G., MOL. CELL. BIOL., vol. 4, 1985, pages 1642 - 1643 |
SUSUMU M. ET AL., NATURE, vol. 315, 1985, pages 592 - 594 |
TAKEBE ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 |
VERDINE, G.L., NATURE (ENGLAND), vol. 384, 7 November 1996 (1996-11-07), pages 11 - 13 |
WANG A. ET AL., SCIENCE, vol. 224, pages 1431 - 1433 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
WILBUR, W.J.; LIPMAN, D.J., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 726 - 730 |
WRIGHTON, N.C. ET AL., SCIENCE (UNITED STATES), vol. 273, 26 July 1996 (1996-07-26), pages 458 - 464 |
ZOLLER M.J.; SMITH M., NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 6500 |
ZOLLER, MJ; SMITH, M., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004074483A1 (ja) * | 2003-02-20 | 2006-06-01 | 哲哉 野阪 | Tsg遺伝子ノックアウト動物 |
Also Published As
Publication number | Publication date |
---|---|
US20050164280A1 (en) | 2005-07-28 |
US20020168721A1 (en) | 2002-11-14 |
EP1215284A4 (en) | 2004-05-19 |
US6890735B2 (en) | 2005-05-10 |
US20090197317A1 (en) | 2009-08-06 |
AU6871900A (en) | 2001-04-10 |
EP1215284A1 (en) | 2002-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020036596A (ja) | 新規ヘモポエチン受容体蛋白質、nr10 | |
WO2001023556A1 (fr) | Nouvelle proteine receptrice d'hemopoietine (nr12) | |
US7829083B2 (en) | Antibodies to brain specific membrane protein | |
WO2001009316A1 (fr) | Nouveaux genes codant la proteine kinase / proteine phosphatase | |
WO2002077230A1 (fr) | Variants d'epissage nr10 | |
WO2001009345A1 (fr) | Nouveaux genes codant des proteines kinase et des proteines phosphatase | |
US20090197317A1 (en) | TSG-Like Gene | |
WO2001021792A1 (fr) | Genes transporteurs oatp-b, c, d et e | |
US20090275082A1 (en) | Mast Cell-Derived Membrane Proteins | |
US20070105143A1 (en) | Novel bHLH type transcription factor genes | |
WO2002020770A1 (fr) | Methode de criblage d'un agent antitumoral a l'aide d'une interaction entre une proteine arf et une proteine hk33 | |
JP4590107B2 (ja) | 新規胎児性遺伝子 | |
JP4499926B2 (ja) | 腫瘍抑制遺伝子 | |
WO2001012808A1 (fr) | Nouveaux genes 584 de la famille frizzled | |
WO2001066720A1 (fr) | Genes de souris d'origine adipocyte | |
JP2008099690A (ja) | 新規ヘモポエチン受容体蛋白質、nr12 | |
JP4942904B2 (ja) | zincフィンガードメインを有する新規転写因子 | |
US7067297B2 (en) | Mannosyltransferase polypeptides and polynucleotides encoding them and methods for making and using them | |
WO2001027270A1 (fr) | Gene ys68 associe a l'hematopoiese precoce | |
WO2001083738A1 (fr) | Facteur de regulation de differenciation et de determination du sexe | |
JP2002000279A (ja) | 初期造血に関わるys68遺伝子 | |
JP2004267003A (ja) | ヒト白血球型抗原領域に存在する新規遺伝子 | |
WO2001044470A1 (fr) | Nouvelle helicase d'arn humain appelee helicaine | |
WO2000012712A1 (fr) | Nouveau facteur de differenciation du tissu nerveux | |
WO2001053484A1 (fr) | Proteine wtip interagissant avec wt1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 521736 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10092925 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000956961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000956961 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |